Noureddin 2025 — Pemvidutide Phase 2 MASH Trial

The Lancet

Mazen Noureddin, et al.

Summary

Pemvidutide met the primary endpoint of MASH resolution without worsening fibrosis at 24 weeks and showed hepatic and metabolic effects.

Study Details

Study Design

Randomized placebo-controlled phase 2 trial

Indication

MASH with liver fibrosis

Intervention

Once-weekly pemvidutide vs placebo

Species

Human

Risk of Bias Assessment

Sponsor-funded phase 2